Noticias de PFE_US

Mercado

Noticias del mercado

Últimas noticias sobre PFE_US — 665 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: PFE_US ✕ 665 resultados
07/10/2026 PFE_US — AD HOC NEWS
Pfizer stock pre-market at EUR 24.51: plus 0.41 percent

Pfizer stock is at EUR 24.51 in pre-market trading at Lang & Schwarz, up 0.41 percent versus the EUR

06/10/2026 PFE_US — Yahoo Finance
Is Pfizer (PFE) a Good or Bad Investment at Today’s Price?

Pfizer Inc. (NYSE:PFE) was trading at around $27 on October 5, down 1.35% on the day and up 5.18% over twelve months. The shares yield 6.19%. The company paid out 226.32% of its earnings to do it. Those two facts have to be reconciled before anything else about this stock matters. READ ALSO: What is […]

06/10/2026 PFE_US — AD HOC NEWS
Pfizer stock sets November 3 earnings date after guidance raise

Pfizer stock traded at USD 27.50 on October 6, 2026, up 0.31 percent intraday. Q2 revenue reached US

06/10/2026 PFE_US — AD HOC NEWS
Pfizer stock gets a USD 0.43 dividend for December on NYSE

Pfizer raised its 2026 revenue guidance midpoint by USD 500 million after second-quarter growth. Pfi

06/10/2026 PFE_US — Yahoo Finance
Pfizer Declares Fourth-Quarter 2026 Dividend

NEW YORK, October 06, 2026--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, to holders of the Common Stock of record at the close of business on November 6, 2026.

06/10/2026 PFE_US — Top Class Actions
Florida AG sues Pfizer over COVID vaccine safety claims

Florida Attorney General James Uthmeier filed a lawsuit against Pfizer, accusing the biopharmaceutical company of deceiving Florida consumers about the safety risks of its COVID-19 vaccine and whether the vaccine could stop the spread of the virus.

06/10/2026 PFE_US — Yahoo Finance
Are Investors Undervaluing Pfizer (PFE) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

06/10/2026 PFE_US — Yahoo Finance
Pfizer’s $6.49 Billion Prevnar Franchise Faces a New Challenger

Key TakeawaysVaxcyte’s VAX-31 matched Pfizer’s Prevnar 20 on all 20 shared serotypes and Merck’s Capvaxive on 17 of 19 in a 4,047-person Phase 3 trial. Prevnar brought in $6.

05/10/2026 PFE_US — STAT
Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.

05/10/2026 PFE_US — Yahoo Finance
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has actually seen in full. What happens when Madrid finally puts the complete data in front of the market?

Página 18 de 34